Paragon 28 Relies on Broad Portfolio to Offset Market Choppiness
The company grew in the high-teens in the third quarter of 2024, as its wide-ranging portfolio insulated it from market...
The company grew in the high-teens in the third quarter of 2024, as its wide-ranging portfolio insulated it from market...
The company grew in the mid-single digits, driven by its broad product portfolio and increasing U.S. market penetration....
The company grew in the mid-single digits on a pro forma basis in the third quarter of 2024 as it...
The company grew 63% on a reported basis in the third quarter of 2024 as it anniversaried its merger with...
The company's orthopedic sales grew in the mid-single digits but headwinds in China will have an ongoing impact into 2025....
The company declined in the mid-single digits during the third quarter of 2024 as it pivots away from Arthrosurface and...
The company grew more than 27% in the third quarter of 2024 as it hones its focus on attaining cash...
The company grew in the mid-single digits in the third quarter of 2024 as it worked through ERP-related issues impacting...
The company's orthopedic sales grew nearly 5% in the third quarter of 2024 but hurricane impacts will impact fourth quarter...
The company's orthopedic sales grew in the double digits during the third quarter of 2024 amid robust volume and demand....
As a guest member you get access to more articles and videos every month.
We’ll send a recovery link to your email.
Return to Homepage